Seagen Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $206.84
- Today's High:
- $208.22
- Open Price:
- $207.8
- 52W Low:
- $116.08
- 52W High:
- $210.5
- Prev. Close:
- $208.13
- Volume:
- 1355533
Company Statistics
- Market Cap.:
- $39.07 billion
- Book Value:
- 13.956
- Revenue TTM:
- $2.16 billion
- Operating Margin TTM:
- -33.12%
- Gross Profit TTM:
- $207.99 million
- Profit Margin:
- -33.55%
- Return on Assets TTM:
- -12.56%
- Return on Equity TTM:
- -26.13%
Company Profile
Seagen Inc had its IPO on 2001-03-16 under the ticker symbol SGEN.
The company operates in the Healthcare sector and Biotechnology industry. Seagen Inc has a staff strength of 3,256 employees.
Stock update
Shares of Seagen Inc opened at $207.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $206.84 - $208.22, and closed at $207.35.
This is a -0.37% slip from the previous day's closing price.
A total volume of 1,355,533 shares were traded at the close of the day’s session.
In the last one week, shares of Seagen Inc have slipped by -0.27%.
Seagen Inc's Key Ratios
Seagen Inc has a market cap of $39.07 billion, indicating a price to book ratio of 8.1587 and a price to sales ratio of 12.7896.
In the last 12-months Seagen Inc’s revenue was $2.16 billion with a gross profit of $207.99 million and an EBITDA of $-644238976. The EBITDA ratio measures Seagen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Seagen Inc’s operating margin was -33.12% while its return on assets stood at -12.56% with a return of equity of -26.13%.
In Q2, Seagen Inc’s quarterly earnings growth was a positive 522.6% while revenue growth was a positive 21.4%.
Seagen Inc’s PE and PEG Ratio
- Forward PE
- 909.0909
- Trailing PE
- 0
- PEG
- 18.5286
Its diluted EPS in the last 12-months stands at $-3.86 per share while it has a forward price to earnings multiple of 909.0909 and a PEG multiple of 18.5286. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Seagen Inc’s profitability.
Seagen Inc stock is trading at a EV to sales ratio of 11.4293 and a EV to EBITDA ratio of -38.8593. Its price to sales ratio in the trailing 12-months stood at 12.7896.
Seagen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.50 billion
- Total Liabilities
- $762.90 million
- Operating Cash Flow
- $133.09 million
- Capital Expenditure
- $49.23 million
- Dividend Payout Ratio
- 0%
Seagen Inc ended 2023 with $3.50 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.50 billion while shareholder equity stood at $2.62 billion.
Seagen Inc ended 2023 with $0 in deferred long-term liabilities, $762.90 million in other current liabilities, 188000.00 in common stock, $-2540612000.00 in retained earnings and $274.67 million in goodwill. Its cash balance stood at $308.44 million and cash and short-term investments were $1.29 billion. The company’s total short-term debt was $0 while long-term debt stood at $0.
Seagen Inc’s total current assets stands at $1.29 billion while long-term investments were $0 and short-term investments were $983.68 million. Its net receivables were $586.05 million compared to accounts payable of $114.42 million and inventory worth $486.85 million.
In 2023, Seagen Inc's operating cash flow was $133.09 million while its capital expenditure stood at $49.23 million.
Comparatively, Seagen Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $207.35
- 52-Week High
- $210.5
- 52-Week Low
- $116.08
- Analyst Target Price
- $224.83
Seagen Inc stock is currently trading at $207.35 per share. It touched a 52-week high of $210.5 and a 52-week low of $210.5. Analysts tracking the stock have a 12-month average target price of $224.83.
Its 50-day moving average was $197.05 and 200-day moving average was $176.93 The short ratio stood at 6.55 indicating a short percent outstanding of 0%.
Around 91.8% of the company’s stock are held by insiders while 8540% are held by institutions.
Frequently Asked Questions About Seagen Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.